TTOO — T2 Biosystems Income Statement
0.000.00%
Last trade - 00:00- $0.31m
- $10.15m
- $7.19m
Annual income statement for T2 Biosystems, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.34 | 18.1 | 28.1 | 22.3 | 7.19 |
| Cost of Revenue | |||||
| Gross Profit | -8.43 | -2.55 | 7.36 | 1.2 | -8.17 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 60.4 | 59.5 | 71 | 77.5 | 56.9 |
| Operating Profit | -52.1 | -41.4 | -43 | -55.2 | -49.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -59 | -46.8 | -49.2 | -62 | -50.1 |
| Net Income After Taxes | -59 | -46.8 | -49.2 | -62 | -50.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -59 | -46.8 | -49.2 | -62 | -50.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -59 | -46.8 | -49.2 | -62.3 | -50.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6,483 | -1,883 | -1,550 | -1,222 | -18.2 |